Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided early relapse detection with palbociclib plus fulvestrant versus standard adjuvant endocrine therapy in ER-positive HER2-negative breast cancer
2020-004022-36Phase 2Active
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib and fulvestrant in breast cancer (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Started Nov 2021; status: active.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-004022-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004022-36.